National Human Genome Research Institute 
Welcome,         Profile    Billing    Logout  
 1 Product   1 Disease  1 Product   3 Trials   142 News 
4 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
miransertib (MK-7075) / Merck (MSD)
2021-001369-19: An extension study for patients with PROS or Proteus Syndrome currently treated with miransertib. Uno studio di estensione per i pazienti con PROS o sindrome di Proteus attualmente trattati con miransertib.

Not yet recruiting
2
60
Europe
Miransertib, [MK-7075], Capsule, hard
MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
PIK3CA-related overgrowth spectrum (PROS) and Proteus Syndrome (PS) Spettro di crescita eccessiva legata a PIK3CA (PROS) e sindrome di Proteus (PS), (PIK3CA)-related overgrowth spectrum (PROS) and Proteus Syndrome Spettro di crescita eccessiva relativa a PIK3CA (PROS) e sindrome di Proteus, Body processes [G] - Genetic Phenomena [G05]
 
 
NCT04316546: MK-7075 (Miransertib) in Proteus Syndrome

Recruiting
2
45
US
MK-7075 (miransertib)
National Human Genome Research Institute (NHGRI)
Proteus Syndrome
03/26
03/28
MK-7075-006, NCT04980872: A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies

Active, not recruiting
2
60
Europe, US, RoW
Miransertib, MK-7075, ARQ 092
Merck Sharp & Dohme LLC
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
02/30
02/30
NCT03317366: Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies

No Longer Available
N/A
NA
ARQ 092
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)
Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorders
 
 
ManNAc / Fortress, Leadiant Biosci
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
miransertib (MK-7075) / Merck (MSD)
2021-001369-19: An extension study for patients with PROS or Proteus Syndrome currently treated with miransertib. Uno studio di estensione per i pazienti con PROS o sindrome di Proteus attualmente trattati con miransertib.

Not yet recruiting
2
60
Europe
Miransertib, [MK-7075], Capsule, hard
MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
PIK3CA-related overgrowth spectrum (PROS) and Proteus Syndrome (PS) Spettro di crescita eccessiva legata a PIK3CA (PROS) e sindrome di Proteus (PS), (PIK3CA)-related overgrowth spectrum (PROS) and Proteus Syndrome Spettro di crescita eccessiva relativa a PIK3CA (PROS) e sindrome di Proteus, Body processes [G] - Genetic Phenomena [G05]
 
 
NCT04316546: MK-7075 (Miransertib) in Proteus Syndrome

Recruiting
2
45
US
MK-7075 (miransertib)
National Human Genome Research Institute (NHGRI)
Proteus Syndrome
03/26
03/28
MK-7075-006, NCT04980872: A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies

Active, not recruiting
2
60
Europe, US, RoW
Miransertib, MK-7075, ARQ 092
Merck Sharp & Dohme LLC
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
02/30
02/30
NCT03317366: Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies

No Longer Available
N/A
NA
ARQ 092
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)
Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorders
 
 
ManNAc / Fortress, Leadiant Biosci
No trials found

Download Options